Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: Results of a retrospective case review

American Journal of Hematology

Volumn 86, Issue 6, 2011, Pages 467-470

  Figaro, M Kathleen ^a   Clayton, Warren ^a   Usoh, Chinenye ^b   Brown, Kara ^b   Kassim, Adetola ^c   Lakhani, Vipul T ^a   Jagasia, Shubhada ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; LENALIDOMIDE;

ARTICLE; BONE MARROW SUPPRESSION; COLD SENSITIVITY; CONSTIPATION; DISEASE ASSOCIATION; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MEDICAL RECORD; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; THYROID DISEASE; THYROID FUNCTION; THYROID HORMONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; THALIDOMIDE; THYROID DISEASES; THYROID FUNCTION TESTS;

EID: 79956127929     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22008     Document Type: Article

References (23)

1. Stein EM, Rivera C. Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma. Thyroid 2007; 17: 681-683.
2. Kurtin SE, List AF. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. Clin Lymphoma Myeloma 2009; 9: E10-E13.
3. Choueiri TK, Dreicer R, Rini BI, et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 2006; 107: 2609-2616.
4. Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 2005; 93: 613-619.
5. Anderson KC. Lenalidomide and thalidomide: Mechanisms of action-similarities and differences. Semin Hematol 2005; 42: S3-S8.
6. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.
7. Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: A comparative analysis of 411 patients. Blood 2010; 115: 1343-1350.
8. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
9. List A. Lenalidomide-A transforming therapeutic agent in myelodysplastic syndromes. Clin Lymphoma Myeloma 2009; 9 Suppl 3: S302-S304.
10. Delforge M, Blade J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues. Lancet Oncol 2010; 11: 1086-1095.
11. Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010; 36 Suppl 2: S24-S32.
12. Badros AZ, Siegel E, Bodenner D, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002; 112: 412-413.
13. de Savary N, Lee R, Vaidya B. Severe hypothyroidism after thalidomide treatment. J R Soc Med 2004; 97: 443.
14. Menon S, Habermann T, Witzig T. Lenalidomide-associated hypothyroidism. Leuk Lymphoma 2007; 48: 2465-2467.
15. Giagounidis A, Fenaux P, Mufti GJ, et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008; 87: 345-352.
16. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86-93.
17. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
18. Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-related fatigue: The scale of the problem. Oncologist 2007; 12 Suppl 1: 4-10.
19. Thomas J. Cancer-related constipation. Curr Oncol Rep 2007; 9: 278-284.
20. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009; 6: 219-228.
21. Tauchmanova L, Selleri C, Rosa GD, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 2002; 95: 1076-1084.
22. Kurtin SE. Hypothyroidism: A growing complication of cancer treatment. Oncology (Williston Park) 2009; 23: 41-45.
23. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81-83.